Ipatasertib


CAS No. : 1001264-89-6

(Synonyms: GDC-0068; RG7440)

1001264-89-6
Price and Availability of CAS No. : 1001264-89-6
Size Price Stock
2mg $60 In-stock
5mg $84 In-stock
10mg $120 In-stock
25mg $245 In-stock
50mg $348 In-stock
100mg $540 In-stock
200mg $900 In-stock
500mg $1800 In-stock
1g $3120 In-stock
5 g Get quote
10 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-15186
M.Wt: 458.00
Formula: C24H32ClN5O2
Purity: >98 %
Solubility: H2O : 3.57 mg/mL (ultrasonic;warming;heat to 60°C);DMSO : 100 mg/mL (ultrasonic)
Introduction of 1001264-89-6 :

Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models[1][2]. IC50 & Target:IC50: 5±7 nM (Akt1), 18±10 nM (Akt2), 8±9 nM (Akt3), 3100±705 nM (PKA)[1] In Vitro:Ipatasertib (10 µM; 12, 24 h) suppresses colon cancer cell proliferation by p53 irrespectively activating PUMA in vitro[1].
Ipatasertib (1, 5, 10, 20 μM; 24 h/10 μM; 3, 6, 12, 24 h) up-regulates the expression level of PUMA in a concentration and time dependent manner in HCT116 cells[1].
Ipatasertib increases the mRNA level of PUMA in HCT116 WT, p53−/−, and DLD1 (p53 mutant) cells[1].
Ipatasertib (10 µM; 24 h) induces apoptosis through PUMA/Bax pathway in HCT116 cells[1]. In Vivo:Ipatasertib (30 mg/kg; p.o.; single daily for 15 consecutive days) exhibits PUMA-dependent antitumor activity in HCT116 WT and PUMA−/− cells xenograft nude mice model[1].

Your information is safe with us.